Home › Trial NCT00903175
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
- Trial IDNCT00903175
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorNovartis Pharmaceuticals
- Enrollment471
- Start date2009-10
- ConditionsRenal Cell Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.